Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma

Annals of Surgical Oncology

Volumn 20, Issue 7, 2013, Pages 2166-2171

  Duldulao, Marjun P ^a   Lee, Wendy ^a   Nelson, Rebecca A ^a   Li, Wenyan ^a   Chen, Zhenbin ^a   Kim, Joseph ^a   Garcia Aguilar, Julio ^b  

^a City of Hope ^*  (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CODON; DNA EXTRACTION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECTUM CARCINOMA; TREATMENT RESPONSE; TUMOR BIOPSY; WILD TYPE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY, ADJUVANT; CODON; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84878879143     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2910-0     Document Type: Article

References (26)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-32.
2. Andreyev HJN, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998;90:675-84. (Pubitemid 28222141)
3. Andreyev HJN, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001;85:692-6. (Pubitemid 32929467)
4. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol. 2009;6:519-27.
5. Vaughn CP, ZoBell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosom Cancer. 2011;50:307-12.
6. Buhrman G, Wink G, Mattos C. Transformation efficiency of Q61 ras mutants linked to structural features of the switch regions. Structure. 2007;15:1618-29. (Pubitemid 350213406)
7. Cespedes MV, Sancho FJ, Pavon MA, Parreno M, Casanova I, Pavón MA, et al. K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis. 2006;27:2190-200. (Pubitemid 44644807)
8. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60:6750-6.
9. Guerrero S, Figueras A, Casanova I, Farre L, Lloveras B, Capella G, et al. Codon 12 and codon 13 mutations at the K-ras gene induce different soft tissue sarcoma types in nude mice. FASEB J. 2002;16:1642-4.
10. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812-20.
11. Keohavong P, DeMichele MA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res. 1996;2:411-8. (Pubitemid 26074623)
12. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011;254:486-93.
13. Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254:97-102.
14. Edge SB, Compton CC, Fritz AG, Fritz AG, Greene FL, Trotti III A. American Joint Committee on Cancer (AJCC) cancer staging manual. 7th ed. Chicago: Springer; 2010.
15. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: retrospective consortium analysis. Lancet Oncol. 2010;11:753-62.
16. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19:508-15. (Pubitemid 351325672)
17. Lievre A, Bachet J, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-9. (Pubitemid 351171687)
18. Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg. 2010;251:254-60.
19. Tejpar S, Bokemeyer C, Celik I, et al. KRAS mutations and outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Ann Oncol. 2011;22(Supp 5):v16-7.
20. Gaedcke J, Grade M, Jung K, Schirmer M, Jo P, Obermeyer C, et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol. 2010;94:76-81.
21. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761-74.
22. Halder J, Landen CN, Lutgendorf SK, Li Y, Jennings NB, Fan D, et al. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res. 2005;11:8829-36. (Pubitemid 43005935)
23. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res. 2007;67:6325-32. (Pubitemid 47037515)
24. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000;288:870-4. (Pubitemid 30257738)
25. Samowitz WS, Slattery ML, Sweeney C, Herrick J, Wolff RK, Albertsen H. APC mutations and other genetic and epigenetic changes in colon cancer. Mol Cancer Res. 2007;5:165-70. (Pubitemid 46423997)
26. Vasovcak P, Pavlikova K, Sedlacek Z, Skapa P, Kouda M, Hoch J, et al. Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. PLoS One. 2011;6:e24114.